However, high expression levels of CLDN18 (2+ and 3+ intensity in ≥75% tumor cells) were found in 117/350 (33.4%) patients (98 primary cases, 19 metastases) and 158/350 (45.1%) patients presented at least 50% of the cancer cells stained for CLDN18. This evidence concerns the gene CLDN18 and cancer.